top of page
header

NEWS

Impactful technology

1_US5SNOIYRFqJui28cWXIrQ.jpg
image-asset.jpeg
February 2024

 

Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated with Sepsis in Patients Undergoing Antimicrobial Treatment

14351%2520Borrelia%2520recurrentis_edite
February 2024

 

HelixBind Named a Phase 2 Winner of the LymeX Diagnostics Prize

by HHS and Steven & Alexandra Cohen Foundation

Closeup of a Petri Dish
December 2023

 

USPTO issues HelixBind patent US 11,840,721 covering

improved methods for detecting microbial infections.

Test Tubes
December 2023

 

HelixBind announces the award of $6 million of non-dilutive funding in 2023

to advance the company's RaPID diagnostic platform.

​

petri-dish.jpg
august 2023

​

USPTO issues HelixBind patent US 11,713,330 covering methods for ultrasensitive direct detection

of microorganisms, including Borrelia, the causative pathogen of Lyme Disease.

images.jpg
February 2023

 

USPTO issues HelixBind patent US 11,590,507 covering reagent carriers for fluidic systems.

​

25SCI-SEPSIS-articleLarge.jpg
December 2022
​

HelixBind announces $9 million in non-dilutive financing from the NIH in 2022 to support the

development of assays for the direct detection and identification of infections.

14351%2520Borrelia%2520recurrentis_edite
November 2022

 

HelixBind selected as Phase 1 winner of the LymeX Diagnostics Prize competition from

the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation.

​

image-asset.jpeg
AUGUST 2022
​

USPTO issues HelixBind patent US 11,414,712 covering methods to identify microbial species

direct from complex specimens, such as blood.

Science Lab
August 2022
​

Japanese Patent Office (JPO) issues HelixBind patent JP 7073328 covering multiple aspects

of HelixBind’s sample-to-answer automated device.

​

ACEP_0317_pg1a_slider.png
March 2022
​

Japanese Patent Office (JPO) issues HelixBind patent JP 7046603 covering the company’s method

for the identification of microbial infections directly from human specimens.

​

image-asset.jpeg
MARCH 2022
​

The China National Intellectual Property Administration (CNIPA) issues HelixBind

patent number CN 109414695 covering certain aspects of its integrated fluidic devices.

Test Tubes
august 2021
​

USPTO issues HelixBind patent US 11,091,814 covering the methods

to detect bacterial and/or fungal genomic material in a sample.

25SCI-SEPSIS-articleLarge.jpg
June 2021
​

HelixBind Awarded $3MM NIH Grant to Support Testing of Its

RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis.

Closeup of a Petri Dish
AUGUST 2020

 

FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test.

​

bottom of page